New hope for chronic hives? early trial underway

NCT ID NCT07005713

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This early-stage study tests a new drug, BGB-16673, in adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger). The main goal is to check safety and how the drug moves through the body. About 34 participants will receive either the drug or a placebo, and researchers will also track changes in hive and itch scores.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chengdu Second Peoples Hospital

    Chengdu, Sichuan, 610021, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Hangzhou First Peoples Hospital

    Hangzhou, Zhejiang, 310006, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100000, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 630014, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, 410008, China

Conditions

Explore the condition pages connected to this study.